European venture capital firm Sofinnova has launched Biovelocita, an investment strategy dedicated to the creation and acceleration of biotech startups in Europe. The firm said it had a created a new team for Biovelocita and the new venture was inspired by Italy’s first biotech accelerator, BiovelocITA, co-founded by Gabriella Camboni, Silvano Spinelli and Sofinnova Partners…
The Spanish city of Barcelona has been identified as the second-best hub on the continent for biotech investment, according to a report from CPHI. At a country level, meanwhile, the CPHI Annual Report expected Spain would emerge as the sixth country in the world and third in Europe with the greatest “pharma growth potential” by…
How investors in the biotech sector can benefit from artificial intelligence’s increasing importance in drug discovery and development purposes Artificial intelligence and machine-learning algorithms are disruptive technologies that are having a twofold impact on the drug discovery process. First, the technology can be applied to save time and money during the process of identifying molecular…
Gareth Blades on the differing attractions of the pioneers, enablers and adopters of genetic sequencing In one of my favourite childhood films, Jurassic Park, Dr Ian Malcolm – perfectly played by Jeff Goldblum – cautions that “genetic power’s the most awesome force the planet’s ever seen”. That was 30 years ago – and it is…
Virus mutations and public scrutiny will make it tough for firms to cash in on a cure
New fund supports development of cancer diagnostics and treatments and seeks to identify breakthrough innovations
Luxembourg-domiciled Sicav will target long-term growth in the fast-growing biotechnology sector
A raft of disruptive technology funds are now available in Europe. How should selectors navigate this complex new area?
The biotech sector is going through a renaissance as innovation takes off according to one successful fund manager, but data shows that performance over the last three years has been far less than stellar.
In the decade since the financial crisis, pharmaceuticals, healthcare and bioscience-focused funds have significantly outperformed the MSCI World index.
The biotechnology sector is on the cusp of potentially revolutionary developments, says disruptive opportunities specialist Wesley Lebeau, but the journey is not without pitfalls.
As the dust (hopefully soon) starts to settle on last week’s market carnage, investors are out pointing fingers at the biggest losers, and speculating on whether they could be tomorrow’s big winners.
